ARK Investment Management LLC Boosts Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

ARK Investment Management LLC raised its position in UroGen Pharma Ltd. (NASDAQ:URGN) by 15.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 140,148 shares of the company’s stock after acquiring an additional 18,514 shares during the period. ARK Investment Management LLC owned approximately 0.60% of UroGen Pharma worth $1,493,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its position in shares of UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after purchasing an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets raised its stake in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after buying an additional 5,890 shares during the last quarter. Intech Investment Management LLC acquired a new stake in UroGen Pharma in the third quarter worth about $155,000. Verition Fund Management LLC purchased a new stake in shares of UroGen Pharma during the third quarter worth about $168,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of UroGen Pharma during the third quarter worth about $249,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Price Performance

Shares of NASDAQ:URGN opened at $9.36 on Thursday. UroGen Pharma Ltd. has a twelve month low of $9.21 and a twelve month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market cap of $219.53 million, a PE ratio of -2.97 and a beta of 1.08. The company’s 50 day moving average is $10.61 and its 200 day moving average is $12.03.

Analysts Set New Price Targets

Several brokerages recently commented on URGN. HC Wainwright reaffirmed a “buy” rating and issued a $64.00 price objective on shares of UroGen Pharma in a research report on Tuesday. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Tuesday, February 18th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $40.00.

Insider Activity

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.